• Huonslab has successfully filed a new patent for the subcutaneous (SC) formulation of Infliximab co-formulated with HyDIFFUZE™ (rHuPH20), following previous patent filings for SC Trastuzumab/HyDIFFUZE™ (rHuPH20) and SC Rituximab/HyDIFFUZE™ (rHuPH20).

Huonslab Co., Ltd. ("Huonslab"), a subsidiary of Huons Global (KOSDAQ: 084110), today announced that its abstract titled “The Role of HyDIFFUZE™ in Co-formulation with Subcutaneous Infliximab” has been selected for poster presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting, taking place on April 28, 2025.

The study demonstrated that HyDIFFUZE™ (rHuPH20) significantly improves the relative bioavailability of co-formulated infliximab compared to infliximab without rHuPH20 when administered subcutaneously.

These findings suggest that co-formulation with HyDIFFUZE^TM (rHuPH20) may reduce the required dose of infliximab while maintaining equivalent therapeutic efficacy and potentially extending dosing interval in the maintenance regimen.

Huonslab previously validated the role of HyDIFFUZE™ (rHuPH20) as a locally acting, transient permeation enhancer for subcutaneous delivery of high-dose, high-volume biotherapeutics, supported by dye dispersion studies in nude mice and in vivo comparative pharmacokinetic (PK) studies in Sprague-Dawley rats.

In parallel, Huonslab is currently conducting a pivotal Phase 1 clinical trial in South Korea for Hydizyme™, a stand-alone recombinant human hyaluronidase (rHuPH20) drug product, with the goal of obtaining product approval from the Ministry of Food and Drug Safety (MFDS) by 2026.

“Huonslab is committed to converting high-dose, high-volume antibody-based biotherapeutics from intravenous (IV) infusion to subcutaneous (SC) injection using human hyaluronidase PH20,” said Dr. Young Sun Lee, Chief Business Officer of Huonslab.

Lee added, “Our HyDIFFUZE™ (rHuPH20) drug delivery technology is redefining the landscape of SC antibody development and expanding patient access to more convenient and effective subcutaneous antibody therapies.”

About Huonslab Co., Ltd.

Huonslab is a subsidiary of Huons Global Co., Ltd., S. Korea, a fast-paced Bio, Pharmaceuticals & Healthcare business holding company with more than 2,200 employees, worldwide.

Huonslab was established in 2018 as a dedicated biologics R&D organization and with a mission to innovate human hyaluronidase-based biologics SC delivery field with its proprietary drug delivery platform, HyDIFFUZE™.

Huonslab has a well-balanced and patient-centric pipeline including HLB3-002 as a lead candidate in the registration study P1, and followed by other non-clinical developments in Alzheimer’s, Obesity and Diabetes.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250402574261/en/

Huonslab is committed to converting high-dose, high-volume antibody-based biotherapeutics from intravenous (IV) infusion to subcutaneous (SC) injection using human hyaluronidase PH20.